Dynavax Technologies
Dynavax, a US biopharmaceutical firm, develops and markets novel vaccines, including a hepatitis B vaccine and COVID-19 research.
Founded
1996Dynavax, a US biopharmaceutical firm, develops and markets novel vaccines, including a hepatitis B vaccine and COVID-19 research.
Official pages and third-party coverage in one index.
dynavax.com12 items across 11 mapped pages · Crawled Sep 25, 2026
Official pages and third-party coverage in one index
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
Dynavax is proud to offer comprehensive and highly competitive benefits to our U.S. based employees and their families.
Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients.
We are a dynamic team with diverse backgrounds, and we like it that way. Our employees thrive in our collaborative, inspiring, and fast-paced environment.
The Dynavax Technologies management team is comprised of industry veterans that have extensive expertise in drug discovery, development and commercialization.
We are committed to being more than innovators: we strive to be trusted partners, working with integrity and compassion to build a healthier, more resilient world for today and for generations to come.
Dynavax GmbH (Dynavax Europe), is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals.
Dynavax Technologies Corporation, 2100 Powell Street Suite 900, Emeryville, CA 94608
Dynavax Technologies is focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.
Dynavax Technologies is focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.
These Terms of Use are entered into by and between you and Dynavax Technologies Corporation, Dynavax GmbH and their respective subsidiaries and affiliates (“Dynavax,” “we,” “us” or “our”). The following Terms of Use, together with the Privacy Notice (collectively, these “Terms”), govern your access to and use of the websites found at dynavax.com, heplisavb.com, any other websites owned and controlled by us that link to these Terms and any of these websites’ subdomains (“our Sites” or “these Site
Dynavax Technologies is focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.